Pet Longevity Spending Pushes a $165 Billion Market

Bloomberg reported that US pet spending is projected to reach $165 billion in 2026 as owners extend human longevity treatments — supplements, red light therapy and drugs including rapamycin — to their dogs, while veterinarians caution that many of the interventions remain unproven.

The anti-aging industry that grew up around human beings has found a new customer base: the family dog. Bloomberg News national health care reporter Anna Edney, speaking with hosts Joe Mathieu and Carol Massar on Bloomberg Markets, described owners buying supplements, red light therapy devices and prescription drugs including rapamycin in the hope of adding healthy years to their pets’ lives. Veterinarians, she noted, are urging caution, because most of what is being sold has not been shown to work.

The number that frames the story is the size of the wallet involved. US pet spending is projected to reach $165 billion in 2026. That is the pool from which longevity products are trying to carve a share, and it is why a consumer behavior that looks eccentric at the individual level matters at the sector level.

Why longevity products migrated from people to dogs

The path is short. The same owner who takes a shelf of supplements, tracks sleep on a wrist device and reads about metabolic aging is already primed to ask why the dog should not get the same. Dogs age visibly and quickly, which makes the emotional case urgent in a way that human longevity marketing never quite achieves. A ten-year-old retriever slowing on the stairs is a deadline.

Rapamycin is the most striking item on the list because it is a real prescription drug with a real mechanism, not a shelf-stable powder. Using it to extend canine lifespan is an experimental idea, and that is precisely the veterinarians’ objection: an intervention borrowed from human medicine and applied to an animal outside an approved indication carries risks that a supplement label does not. Red light therapy sits at the other end of the spectrum — a device sale, low regulatory friction, and correspondingly thin evidence for the claims stacked on top of it.

What unites them commercially is that none of them requires the buyer to wait for proof. Pet owners are not running trials; they are acting on affection and available information. That makes demand fast-moving and largely insensitive to the kind of clinical rigor that governs human prescribing.

Where the money actually lands in a $165 billion market

Pet spending is not one market but four stacked on each other, and longevity touches each differently.

• Food and treats — the largest and stickiest layer, where “healthy aging” is a labeling and formulation story rather than a drug story.
• Veterinary services — clinics capture the consultation, diagnostics and monitoring that any serious longevity protocol implies, whether or not the underlying treatment works.
• Animal pharmaceuticals — the segment with genuine regulatory barriers to entry, and therefore the one where an approved aging-related therapy would be worth the most.
• Supplements and devices — the lowest barrier, the fastest to market, and the part of the market veterinarians are warning about most loudly.

The asymmetry is worth noting. The segment where money is easiest to collect today is the one with the least evidence behind it, while the segment that could produce a durable franchise — a properly studied, properly labeled therapy for canine aging — is slow, expensive and uncertain. Investors reading the theme should be clear about which one they are buying.

Vets are the gatekeepers, and they are pushing back

The caution coming from veterinarians is not a footnote to this trend; it is the main variable in how it develops. Clinics are the distribution channel for anything prescription-grade and the trusted voice for everything else. If the profession broadly declines to endorse off-label longevity protocols, the market stays concentrated in direct-to-consumer supplements and devices, where margins can be good but claims are legally fragile.

That fragility is the risk that tends to get underpriced. Health claims made about an unproven product invite the attention of regulators and of plaintiffs’ lawyers. A category built on hope, sold without evidence, into an emotionally invested buyer is a familiar setup — and it has a familiar ending when someone decides to test the marketing language.

The constructive version of the same trend is more interesting. Owners willing to pay for aging-related care are also willing to pay for diagnostics, more frequent visits, dental work, mobility support and end-of-life care. Even if rapamycin for dogs turns out to be a dead end, the underlying willingness to spend on an older animal is real, and that flows to clinics and pharma regardless of which specific product wins.

A consumer story with harder edges than it looks

Pet spending is often described as recession-resistant, and there is truth in it: people cut their own discretionary purchases before they cut the dog’s. But “resistant” is not “immune,” and the longevity layer is the most discretionary part of the stack. A supplement regimen and a light-therapy device are the first things to go if household budgets tighten; kibble and a rabies shot are the last.

That matters for how the theme trades. The equity backdrop into the story was flat rather than fearful — the S&P 500 tracking fund (NYSEARCA: SPY) closed at $776.34, down 0.20% on the day, on Friday, Aug. 14, 2026, with the Nasdaq 100 fund (NASDAQ: QQQ) at $731.07, off 0.14%, and the Dow tracker (NYSEARCA: DIA) at $536.80, down 0.21%, according to the market data as of 20:00 GMT that day. Nothing in those closes suggests a market repricing consumer health; the pet longevity story is a bottom-up demand shift, not a macro event.

What would turn a trend into a business

Three things are worth watching. First, whether any canine aging therapy moves through a formal regulatory process rather than staying in off-label use — that is the difference between a fad and a franchise. Second, whether veterinary associations soften or harden their guidance, because clinic endorsement is the switch that opens the larger channel. Third, whether the big food and retail players fold “healthy aging” into mainstream product lines, which would broaden the addressable spend far beyond the enthusiast owner currently buying rapamycin for a middle-aged labrador.

For now, the honest read is that a very large consumer market is developing a small, fast-growing and evidentially shaky appendage. The $165 billion projection for 2026 is the reason to pay attention. The veterinarians’ warning is the reason not to assume the money follows the hype.

Key facts

• US pet spending, 2026 projection: $165 billion
• Treatments cited: Supplements, red light therapy, rapamycin
• Veterinary position: Caution urged; treatments unproven
• Market backdrop (SPY close): $776.34, -0.20%, as of Aug. 14, 2026, 20:00 GMT

Frequently asked questions

How large is the US pet market expected to be in 2026?

US pet spending is projected to reach $165 billion in 2026, according to figures cited by Bloomberg News national health care reporter Anna Edney. That total spans food and treats, veterinary services, animal pharmaceuticals, and the supplements and devices where longevity products are currently concentrated. Longevity-specific spending is a small but fast-growing slice of that overall figure.

What longevity treatments are pet owners giving their dogs?

Bloomberg reported that owners are using supplements, red light therapy devices and prescription drugs including rapamycin in an effort to extend their dogs’ healthy lifespans. These are the same categories of intervention many people pursue for themselves, transferred to pets. The specific protocols vary widely because there is no established standard of care for canine longevity.

Why are veterinarians warning against these treatments?

Veterinarians are urging caution because the treatments are unproven. Applying a human prescription drug such as rapamycin to a dog for an aging-related purpose sits outside established veterinary practice, and supplements and light-therapy devices generally lack rigorous evidence supporting the claims made for them. The concern is that owners are acting on hope rather than demonstrated benefit.

Which parts of the pet industry benefit most from this trend?

Veterinary clinics capture consultations, diagnostics and monitoring associated with any aging-related care. Supplement and device sellers have the lowest barrier to entry and the fastest route to revenue. Animal pharmaceutical companies face the highest regulatory hurdles but would own the most durable franchise if an aging-related therapy were formally studied and approved.

Is pet spending resistant to economic downturns?

Core pet spending — food and basic veterinary care — tends to hold up better than most discretionary categories, because owners cut their own purchases first. Longevity products are the exception: supplements, devices and experimental drug protocols are the most discretionary layer of the stack and would likely be the earliest casualties of a household budget squeeze.

What was the broader market doing when this story ran?

Equity benchmarks were essentially flat at the most recent close before publication. As of 20:00 GMT on Friday, Aug. 14, 2026, the S&P 500 tracking fund SPY closed at $776.34, down 0.20%; the Nasdaq 100 fund QQQ at $731.07, down 0.14%; and the Dow tracker DIA at $536.80, down 0.21%. Nothing suggested a macro repricing of consumer health spending.

Sources

• Longevity Boom Reaches America’s Pets — Bloomberg Markets

Photo: Mikhail Nilov · Pexels Licence — source